Recommended Trivalent Seasonal Influenza Vaccines for Different Age Groups: United States, 2011–2012 Influenza Season

VaccineTrade NameManufacturerPresentationOvalbumin Content, μg of Ovalbumin per 0.5-mL DoseThimerosal Mercury Content, μg of Hg per 0.5-mL DoseAge Group
    TIVFluzoneSanofi Pasteur, Swiftwater, PA0.25-mL prefilled syringe∼0.1a0.06–35 mo
0.5-mL prefilled syringe∼0.1a0.0≥36 mo
0.5-mL vial∼0.1a0.0≥36 mo
5.0-mL multidose vial∼0.1a25.0≥6 mo
    TIVFluzone intradermalSanofi Pasteur, Swiftwater, PA0.1-mL prefilled microinjectionNot cited0.018–64 y
    TIVFluzone HDSanofi Pasteur, Swiftwater, PA0.5-mL prefilled syringe∼0.1a0.0≥65 y
    TIVFluvirinNovartis, East Hanover, NJ0.5-mL prefilled syringe≤1.0b<1.0≥4 y
5.0-mL multidose vial≤1.0b25≥4 y
    TIVFluarixGlaxoSmithKline, King of Prussia, PA0.5-mL prefilled syringe≤0.05b0.0≥3 y
    TIVFluLavalGlaxoSmithKline, King of Prussia, PA5.0-mL multidose vial≤1.0b25.0≥18 y
    TIVAfluriaCSL Biotherapies, King of Prussia, PA0.5-mL prefilled syringe≤1.0b0≥9c
5-mL multidose vial≤1.0b25.0≥9c
    LAIVFluMistMedImmune, Gaithersburg, MD0.2-mL sprayerNot cited0.02–49 y
  • a Data obtained from Sanofi Pasteur (personal communication, 2011) suggests that the residual egg protein (expressed as ovalbumin) in Fluzone vaccine or in Fluzone High-Dose vaccine is typically on the order of 0.1 μg per dose.

  • b Data are from the package inserts, many of which have been updated for the 2011–2012 season.

  • Data sources: American Academy of Pediatrics, Committee on Infectious Diseases. Pediatrics. 2010;126(4):816–826; Centers for Disease Control and Prevention. MMWR Recomm Rep. 2010;59(RR-8):1–62; and Centers for Disease Control and Prevention. Morb Mortal Wkly Rep. 2011;60 (Early Release):1–6.

  • c Age indication per package insert is ≥5 years; however, the ACIP recommends Afluria not be used in children aged 6 months through 8 years because of increased reports of febrile reactions noted in this age group. If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child aged 5 through 8 years of age who has a medical condition that increases the child's risk for influenza complications, Afluria can be used; however, providers should discuss with the parents or caregivers the benefits and risks of influenza vaccination with Afluria before administering this vaccine.